Journal of General Internal Medicine

, Volume 14, Issue 11, pp 699–704 | Cite as

Preventive care in chronic liver disease

  • Thomas R. Riley
  • Jill P. Smith
Clinical Review


OBJECTIVE: To identify preventive care measures that are appropriate for and specific to patients with chronic liver disease and to provide recommendations and information that can be shared with patients.

MEASUREMENTS: A review of the literature was undertaken using MEDLINE from 1970 to present. Priority was given to randomized controlled studies, but case reports, case-control studies, and reviews were included.

MAIN RESULTS: Evidence for the avoidance of alcohol and other toxic substances, immunizations, and dietary modifications for chronic liver disease is summarized. In addition, measures that are effective in the mitigation of the complications of cirrhosis are reviewed.

CONCLUSIONS: Preventive care can play an important role in patients with chronic liver diseases. Based on the existing data, the preventive strategies of alcohol avoidance, hepatitis vaccination, avoidance of NSAIDs nonsteroidal anti-inflammatory drugs, iron supplementation when appropriate, and a low-fat diet are prudent in patients with chronic liver disease. Once cirrhosis develops, screening for hepatocellular cancer with α-fetoprotein testing and ultrasound, and screening for varices by endoscopy are justified.

Key Words

liver diseases prevention hepatitis cirrhosis immunization diet 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alter JM, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med. 1992;327:1899–905.PubMedCrossRefGoogle Scholar
  2. 2.
    Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med. 1996;125:634–9.PubMedGoogle Scholar
  3. 3.
    Poupon RE, Balkau B, Eschwege E, et al. A multicenter, controlled trial of ursodial for the treatment of primary biliary cirrhosis. N Engl J Med. 1991;324:1548–54.PubMedCrossRefGoogle Scholar
  4. 4.
    Propst A, Propst T, Zangerl G, et al. Prognosis and life expectancy in chronic liver disease. Dig Dis Sci. 1995;40:1805–15.PubMedCrossRefGoogle Scholar
  5. 5.
    Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med. 1997;337:1705–14.PubMedCrossRefGoogle Scholar
  6. 6.
    Scheig R. Effects of ethanol on the liver. Am J Clin Nutr. 1970;23:467–73.PubMedGoogle Scholar
  7. 7.
    Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology. 1998;27:914–9.PubMedCrossRefGoogle Scholar
  8. 8.
    O’Conner PG, Schottenfeld RS. Patients with alcohol problems. N Engl J Med. 1998;592–601.Google Scholar
  9. 9.
    Wang JY, Lee SD, Tsai YT, et al. Fulminant hepatitis A in chronic HBV carrier. Dig Dis Sci. 1986;31:109–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Conteas C, Kao H, Rakela J, et al. Acute type A hepatitis in three patients with chronic HBV infection. Dig Dis Sci. 1983;28:684–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 1995;90:201–5.PubMedGoogle Scholar
  12. 12.
    Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med. 1989;110:838–9.PubMedGoogle Scholar
  13. 13.
    Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Francis DP. The public’s health unprotected: reversing a decade of underutilization of hepatitis B vaccine. JAMA. 1995;274:1242–3.PubMedCrossRefGoogle Scholar
  15. 15.
    Bader TF. Hepatitis A vaccine. Am J Gastroenterol. 1996;91:217–22.PubMedGoogle Scholar
  16. 16.
    Gardner P, Eickoff T, Poland GA, et al. Adult immunizations. Ann Intern Med. 1996;12:35–40.Google Scholar
  17. 17.
    Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998;27:881–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Hess G, Clemens R, Bienzle U, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol. 1995;46:40–2.PubMedCrossRefGoogle Scholar
  19. 19.
    Andre FE. Summary of safety and efficacy data on a yeast-derived hepatitis vaccine. Am J Med. 1989;87(3A):14S-20S.PubMedCrossRefGoogle Scholar
  20. 20.
    Hughes JM. Prevention of pneumococcal disease. MMWR. 1997;46:1–24.Google Scholar
  21. 21.
    Hughes JM. Prevention and control of influenza. MMWR. 1997;46:1–25.Google Scholar
  22. 22.
    Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 1995;118–27.Google Scholar
  23. 23.
    Speeg KV, Bay MK. Prevention and treatment of drug-induced liver disease. Gastroenterol Clin North Am. 1995;24:1047–64.PubMedGoogle Scholar
  24. 24.
    Carson JL, Willet LR. Toxicity of nonsteroidal anti-inflammatory drugs: an overview of the epidemiological evidence. Drugs. 1993;46S:243–8.Google Scholar
  25. 25.
    Riley TR, Smith JP. Ibuprofen-induced hepatotoxicity in those with chronic hepatitis C: a case series. Am J Gastroenterol. 1998;93:1563–5.PubMedGoogle Scholar
  26. 26.
    Rabinovitz M, Van Thiel DH. Hepatotoxicity of nonsteroidal antiinflammatory drugs. Am J Gastroenterol. 1992;87:1696–1704.PubMedGoogle Scholar
  27. 27.
    Zimmerman HJ, Maddrey WC. Acetaminophen hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology. 1995;22:767–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Flora K, Hahn M, Rosen H, et al. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998;93:139–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Bashir RM, Lewis JH. Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders. Gastroenterol Clin North Am. 1995;24:937–67.PubMedGoogle Scholar
  30. 30.
    Riggio O, Montagnese F, Fiore P, et al. Iron overload in patients with chronic viral hepatitis: how common is it? Am J Gastroenterol. 1997;8:1298–1301.Google Scholar
  31. 31.
    Bisceglie AM, Axiotis CA, Hoofnagle JH, et al. Measurement of iron status in patients with chronic hepatitis. Gastroenterology. 1992;102:2108–13.PubMedGoogle Scholar
  32. 32.
    Olynyk JK, Reddy R, Di Bisceglie AM, et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology. 1995;108:1104–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Van Thiel DH, Friedlander L, Fagiuoli S, et al. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol. 1994;20:410–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Hayashi H, Takikawa T, Nishimura N, et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol. 1994;89:986–8.PubMedGoogle Scholar
  35. 35.
    Guptas RC, Mulhotra S, Lehandekar P, et al. Influence of low iron diet on the efficacy of interferon therapy in patients with chronic liver disease. Presented at the IXth Biennial Scientific Meeting Asian Pacific Association for the Study of the Liver, Kuala Lumpur, Malaysia, January 26–29, 1994.Google Scholar
  36. 36.
    Stal P, Hultcrantz R. Iron increases ethanol toxicity in rat liver. J Hepatol. 1993;17:108–15.PubMedCrossRefGoogle Scholar
  37. 37.
    Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996;23:1464–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74–80.PubMedCrossRefGoogle Scholar
  39. 39.
    Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103–9.PubMedGoogle Scholar
  40. 40.
    Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet in obese patients with fatty liver. J Hepatol. 1997;27:103–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Deems RO, Friedman LS, Friedman MI, et al. Relationship between liver biochemical tests and dietary intake in patients with liver disease. J Clin Gastroenterol. 1994;18:304–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Kleber G, Hasan A, Sauerbruch T. Prophylaxis of first variceal bleeding. Bailliere Clin Gastroenterol. 1992;6:563–80.CrossRefGoogle Scholar
  43. 43.
    DeFranchis R. Prediction of first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med. 1988;319:983–9.CrossRefGoogle Scholar
  44. 44.
    Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med. 1991;324: 1532–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Grace N. Prevention of initial variceal hemorrhage. Gastroenterol Clin North Am. 1992;21:149–61.PubMedGoogle Scholar
  46. 46.
    Angelico M, Carli L, Piat C, et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology. 1993;104:1460–5.PubMedGoogle Scholar
  47. 47.
    Zoli M, Magalotti D, Bianchi G, et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer. 1996;78:977–85.PubMedCrossRefGoogle Scholar
  48. 48.
    Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991;214:221–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Maringhini A, Cottone M, Sciarrino E, et al. Ultrasonography and alpha-fetoprotein, in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci. 1988;33:47–51.PubMedCrossRefGoogle Scholar
  50. 50.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Durand F, Buffet C, Pelleetier G, et al. Screening of hepatocellular carcinoma in French patients. Dig Dis Sci. 1995;40:706–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin Infect Dis. 1998;27:669–76.PubMedGoogle Scholar
  54. 54.
    Gines P, Rimola A, Planus R, et al. Norfloxacin prevents bacterial infection in cirrhosis: results of a double-blind, placebo controlled trial. Hepatology. 1990;12:716–24.PubMedCrossRefGoogle Scholar
  55. 55.
    Campillo B, Dupeyron C, Richardet JP, et al. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effects of long term administration of norfloxacin. Clin Infect Dis. 1998;26:1066–70.PubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 1999

Authors and Affiliations

  • Thomas R. Riley
    • 1
  • Jill P. Smith
    • 1
  1. 1.Received from the Department of Medicine, Section of Gastroenterology and HepatologyPenn State Geisinger Health SystemHershey

Personalised recommendations